Table: Aska Pharmaceutical Holdings -2025/26 group results

ASKA Pharmaceutical Holdings Co

11/05/2026 07:34

May 11 (Reuters)- 
          Aska Pharmaceutical Holdings Co., Ltd. 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2026    Mar 31, 2025   Mar 31, 2027     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           71.13           64.14          73.00                 
               (+10.9 pct)     (+2.1 pct)     (+2.6 pct)               
  Operating        5.83            5.33           6.20                 
               (+9.4 pct)      (-18.0 pct)    (+6.3 pct)               
  Recurring        5.67            5.11           6.10                 
               (+10.9 pct)     (-21.7 pct)    (+7.7 pct)               
  Net
  Net              5.42            5.10           4.80                 
               (+6.3 pct)      (-32.4 pct)    (-11.5 pct)              
  EPS          191.12 yen      179.95 yen     169.11 yen               
  Ann Div       60.00 yen       55.00 yen      65.00 yen               
  -Q2 Div       27.00 yen       25.00 yen      32.00 yen               
  -Q4 Div       33.00 yen       30.00 yen      33.00 yen               
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd..
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T